儿童以MF59佐剂与非佐剂季节性流感疫苗基础免疫的比较:系统评价与Meta分析
该系统评价与Meta分析纳入随机对照试验,比较6-72月龄儿童接种MF59佐剂灭活流感疫苗(aIIV)与非佐剂IIV后的血凝抑制抗体应答。2剂aIIV对甲型和乙型流感病毒的几何平均滴度(GMT)比值较2剂IIV高2.5-3.5倍;1剂aIIV与2剂IIV对甲型病毒应答无显著差异,对乙型病毒较低。
要点
- 2剂aIIV后针对三株疫苗株的GMT较2剂IIV高2.5-3.5倍,6-35月龄点估计更高
- 1剂aIIV vs 2剂IIV对A/H1N1与A/H3N2无显著差异,对B型病毒显著较低
- 作者指出免疫印迹与细胞免疫的长期获益及临床效力试验尚待研究
核心结论
- 2剂MF59佐剂IIV在6-72月龄儿童中较非佐剂IIV持续诱导更好的甲型和乙型流感病毒体液免疫应答,6-35月龄尤为明显;1剂佐剂IIV对甲型病毒的应答与2剂非佐剂IIV相似。
研究设计与样本
- 系统评价与Meta分析,纳入8项随机对照试验;儿童平均年龄28个月(范围6-72个月);按年龄接种每株7.5 μg(6-35月龄)或15 μg(≥36月龄)血凝素;8项试验中7项使用三价疫苗、1项使用四价疫苗。
主要发现
- 2剂aIIV vs 2剂IIV:针对三株疫苗株的接种后GMT比值高2.5-3.5倍,6-35月龄点估计高于年长儿。
- 1剂aIIV vs 2剂IIV:A/H1N1 GMT比值1.0(95% CI 0.5-1.8,p=0.90)、A/H3N2 1.0(95% CI 0.7-1.5,p=0.81),均无显著差异;B型病毒0.6(95% CI 0.4-0.8,p<0.001),显著较低。
- 疫苗不匹配的异源病毒:2剂aIIV vs 2剂IIV的GMT比值A/H1N1为2.0(95% CI 1.1-3.4)、A/H3N2为2.9(95% CI 1.9-4.2)、B谱系为2.1(95% CI 1.8-2.6)。
关键数值与推荐
- 2剂aIIV vs 2剂IIV针对三株疫苗株的GMT比值:2.5-3.5倍(6-72月龄)。
- 1剂aIIV vs 2剂IIV:A/H1N1 1.0(95% CI 0.5-1.8,p=0.90),A/H3N2 1.0(95% CI 0.7-1.5,p=0.81),B型0.6(95% CI 0.4-0.8,p<0.001)。
- 异源病毒2剂aIIV vs 2剂IIV:A/H1N1 2.0(95% CI 1.1-3.4)、A/H3N2 2.9(95% CI 1.9-4.2)、B谱系2.1(95% CI 1.8-2.6)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Identifying optimal priming strategies for children <2 years could substantially improve the public health benefits of influenza vaccines. Adjuvanted seasonal influenza vaccines were designed to promote a better immune response among young vaccine-naïve children. METHODS: We systematically reviewed randomized trials to assess hemagglutination inhibition (HAI) antibody response to MF59-adjuvanted inactivated influenza vaccine (aIIV) versus nonadjuvanted IIV among children. We estimated pooled ratios of post-vaccination HAI geometric mean titer (GMT) for aIIV versus IIV and confidence intervals (CIs) using the pooled variances derived from reported CIs. RESULTS: Mean age was 28 months (range, 6-72 months). Children received vaccines with either 7.5 μg (6-35 months) or 15 μg (≥36 months) hemagglutinin of each strain depending on age. Seven of eight trials administered trivalent vaccines and one used quadrivalent vaccine. Pooled post-vaccination GMT ratios against the three influenza vaccine strains were 2.5-3.5 fold higher after 2-dose-aIIV versus 2-dose-IIV among children 6-72 months, and point estimates were higher among children 6-35 months compared with older children. When comparing 1-dose-aIIV to 2-dose-IIV doses, pooled GMT ratios were not significantly different against A/H1N1 (1.0; 95% CI: 0.5-1.8; p = 0.90) and A/H3N2 viruses (1.0; 95% CI: 0.7-1.5; p = 0.81) and were significantly lower against B viruses (0.6; 95% CI: 0.4-0.8; p < 0.001) for both age groups. Notably, GMT ratios for vaccine-mismatched heterologous viruses after 2-dose-aIIV compared with 2-dose-IIV were higher against A/H1N1 (2.0; 95% CI: 1.1-3.4), A/H3N2 (2.9; 95% CI: 1.9-4.2), and B-lineage viruses (2.1; 95% CI: 1.8-2.6). CONCLUSIONS: Two doses of adjuvanted IIV consistently induced better humoral immune responses against Type A and B influenza viruses compared with nonadjuvanted IIVs in young children, particularly among those 6-35 months. One adjuvanted IIV dose had a similar response to two nonadjuvanted IIV doses against Type A influenza viruses. Longer-term benefits from imprinting and cell-mediated immunity, including trials of clinical efficacy, are gaps that warrant investigation.
引用
- Patel MM, Davis W, Beacham L, et al. Priming with MF59 adjuvanted versus nonadjuvanted seasonal influenza vaccines in children - A systematic review and a meta-analysis. Vaccine. 2019. PMID: 31735505. doi:10.1016/j.vaccine.2019.10.053
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。